News
Drug and biotech news
Last checked: Nov 20, 2026Source: BioPharma Dive, STAT (pharma), FDA press releases, FDA MedWatch, Drugs@FDA (new approvals), openFDA (Class I recalls)
30 stories
- Trade pressSTAT (pharma)Nov 20, 2026STAT+: Pharmalittle: We're reading about Sanofi eyeing Insmed, AI speeding drug development, and more
Sanofi weighs an Insmed takeover, the FDA slams J&J over misleading bladder cancer drug claims, and more pharma news:
- Trade pressSTAT (pharma)Nov 20, 2026STAT+: Early results for Alterome's KRAS drug for pancreas, lung and colon cancer arrive
Alterome presented preliminary Phase 1 results of its drug “selectively” targeting a range of KRAS mutations — drivers of cancers in the pancreas, lung and colon:
- Trade pressBioPharma DiveNov 20, 2026Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
Wall Street analysts rushed to Celldex's defense following the setback. Elsewhere, Isomorphic Labs cut a cancer-focused deal with Merck and Teva's research chief accepted a new job.
- Trade pressBioPharma DiveNov 20, 2026This week in charts: Biotech investors’ China bets are already paying off
This year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024.
- Trade pressSTAT (pharma)Nov 19, 2026STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in China
Big drugmakers tell U.S. House committee they will halt clinical trials at some hospitals in China.
- Trade pressBioPharma DiveNov 19, 2026Sanofi gains FDA clearance for Gaucher disease pill
The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent's looming patent expiration.
- Trade pressSTAT (pharma)Nov 19, 2026STAT+: Lawmakers want U.S. biotech to outcompete China
Lawmakers leading the congressional BIOTech Caucus say Washington needs to act in the sector — and fast:
- Trade pressSTAT (pharma)Nov 19, 2026STAT+: Peptide market poised to explode with new Hims and Noom launches
Two telehealth giants rolled out peptide programs this week after HHS made it easier for compounding pharmacies to offer drugs like BPC-157.
- Trade pressBioPharma DiveNov 19, 2026China could ‘corner’ biopharma sector with new plan, US panel warns
A commission called on U.S. lawmakers to act quickly to prevent an "overdependence" on China that could leave American patients "vulnerable to supply chain weaponization."
- Trade pressSTAT (pharma)Nov 19, 2026STAT+: MAHA PAC’s steakhouse spend
MAHA PAC's curious spending decisions, and a close look at what's next for the FDA.
- Trade pressBioPharma DiveNov 19, 2026With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
The product of a collaboration with Alnylam, Livsayis is now Regeneron's first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
- Trade pressSTAT (pharma)Nov 19, 2026STAT+: Pharmalittle: We're reading about a Merck AI deal, China and the pharma supply chain, and more
Merck is entering a research collaboration with Isomorphic Labs, the AI drug designer built on a Nobel-winning technology
- Trade pressSTAT (pharma)Nov 19, 2026STAT+: Merck, Isomorphic Labs partner to develop oncology drug candidates
Merck and Isomorphic Labs said they are entering into a research collaboration to discover small molecule candidates in oncology.
- Trade pressSTAT (pharma)Nov 18, 2026STAT+: NIH to move last group of its research chimps to a sanctuary
The last chimpanzees owned by the U.S. government and still living in a laboratory will be moved to a sanctuary next year.
- Trade pressSTAT (pharma)Nov 18, 2026STAT+: 7 burning questions about the FDA’s post-Overton future
STAT tackles the most important questions about the FDA's uncertain future.
- Trade pressBioPharma DiveNov 18, 2026‘Selling and marketing snake oil’: The debate over compounded GLP-1s
Proponents of compounding argue it increases access, lowers prices and helps patients who may need individualized versions of a drug. But there are serious concerns, experts said at the HLTH conference.
- Trade pressBioPharma DiveNov 18, 2026White House pulls nomination for FDA nominee Overton
The sudden end of Heidi Overton's candidacy likely ensures a Democrat-controlled Congress will choose the FDA's next leader - but shouldn't disrupt the agency, analysts say.
- Trade pressBioPharma DiveNov 18, 2026Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.
- Trade pressSTAT (pharma)Nov 18, 2026STAT+: FDA discloses reasons for rejecting Summit drug
The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:
- Trade pressSTAT (pharma)Nov 18, 2026STAT+: Pharmalittle: We're reading about Overton FDA nomination being yanked, a Merck setback, and more
The Trump administration is pulling the nomination of Heidi Overton to lead the FDA over concerns she lacked support to get confirmed by the Senate
- Trade pressBioPharma DiveNov 18, 2026FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
- Trade pressBioPharma DiveNov 17, 2026Roche breast cancer pill cleared by FDA
Wilserdly's U.S. approval is seen by analysts as a "key first step" in an important launch for Roche, which has claimed the drug could become its top-selling product.
- Trade pressSTAT (pharma)Nov 17, 2026STAT+: Flagship opens biotech-creation outpost in the U.K.
Flagship is putting up 100 million pounds to start “AI-native platform companies" focused on human and planetary health in the U.K.:
- Trade pressSTAT (pharma)Nov 17, 2026STAT+: 'Medicare for More' gains traction
Democrats coalesce around a new health care policy, and Trump's new chief of staff embraces MAHA.
- Trade pressSTAT (pharma)Nov 17, 2026STAT+: Pharmalittle: We're reading about a Roche breast cancer pill, obesity drugs in children, and more
The FDA approved a breast cancer drug from Roche, teeing up the launch of what the company has said could become its top-selling product
- Trade pressSTAT (pharma)Nov 16, 2026STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
The FDA approved a new breast cancer drug from Roche, teeing up the launch of a medicine the company has said could become its top-selling product ever.
- Trade pressSTAT (pharma)Nov 16, 2026STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC
The supplement NAC has been widely available for years, but exists in a legal gray area.
- Trade pressSTAT (pharma)Nov 16, 2026STAT+: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns
How obesity medications may become the next big battleground over access to medicines in lower-income countries.
- Trade pressSTAT (pharma)Nov 16, 2026STAT+: Biotech's rebound isn't lifting all boats equally
Biotech is having a good year, though you wouldn't necessarily know it from how investors are treating positive clinical data.
- Trade pressSTAT (pharma)Nov 16, 2026STAT+: Pharmalittle: We're reading about GLP-1 use, Covid-19 vaccine investment returns, and more
During July and August 2025, approximately 1 in 10 U.S. adults reported taking a GLP-1 medication during the previous year
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.